More Litigation Coming? Insulin MDL Gets Boost from FTC Report
By Lisa Willis
Jan 17, 2025
Insulin MDL litigation is gaining momentum, bolstered by a fresh FTC report. Tal Lifshitz and Ben Wotlanzki emphasize that the agency’s findings reinforce allegations of anticompetitive behavior and pricing manipulation. They predict a surge in lawsuits targeting insulin manufacturers, setting the stage for intensified legal scrutiny and robust multidistrict litigation activity.
Click here to read the original article.